Could it be VEXAS?

Hippolyte Guerineau,Milena Kohn,Antoine Al Hamoud,Jacques Sellier,Jennifer Osman,Aurélie Cabannes-Hamy,Guerineau, Hippolyte

DOI: https://doi.org/10.1007/s00277-024-05750-8

2024-04-10

Annals of Hematology

Abstract:We report the case of the youngest patient described with VEXAS syndrome associated with MDS-IB1, successfully treated with azacitidine-venetoclax and allogeneic stem cell transplant.

hematology

What problem does this paper attempt to address?

Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report

Michael Loschi,Christian Roux,Isabelle Sudaka,Corinne Ferrero-Vacher,Alice Marceau-Renaut,Nicolas Duployez,Thierry Passeron,Thomas Cluzeau

DOI: https://doi.org/10.1038/s41409-021-01544-y

2022-01-09

Bone Marrow Transplantation

Abstract:To the Editor:VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a newly described entity linked to somatic mutation of UBA1, encompassing inflammatory disorders and hematological malignancies. Patients experiments symptoms related to inflammatory manifestations on the skin, joints, lungs. Most patients are refractory to usual anti-inflammatory or immunosuppressive treatments. Half of them will develop hematological diseases, mostly myelodysplastic syndromes. VEXAS patients with hematological malignancies have a poor outcome and no curative option has been described so far. Because in the first reported cohort of VEXAS patients the UBA1 mutation was only found in hematopoietic stem cells but not in fibroblasts, we hypothesized that bone marrow transplantation would provide a cure for the disease. Here we report the case of a VEXAS patient who successfully received an allogeneic hematopoietic stem cell transplantation as a curative option.

oncology,immunology,hematology,transplantation
Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience

Ava Diarra,Nicolas Duployez,Elise Fournier,Claude Preudhomme,Leonardo Magro,Bruno Quesnel,Maël Heiblig,Pierre Sujobert,Fiorenza Barraco,Marie Balsat,Quentin Scanvion,Eric Hachulla,David Launay,Ibrahim Yakoub-Agha,Valérie Coiteux,Louis Terriou,

DOI: https://doi.org/10.1182/bloodadvances.2021004749

IF: 7.642

2022-02-04

Blood Advances

Abstract:Abstract The recently described vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is caused by somatic mutations in UBA1. Patients with VEXAS syndrome display late-onset autoinflammatory symptoms, usually refractory to treatment, and hematologic abnormalities. The identification of an easily-accessible specific marker (UBA1 mutations) is of particular interest as it allows the convergence of various inflammatory and hematological symptoms in a unique clinico-biological entity and gives the opportunity to design specific treatment strategies. Here we retrospectively identified 6 patients with VEXAS syndrome who underwent allogeneic hematopoietic stem cell transplantation (ASCT). To date, no treatment guidelines have been validated. In 4 patients, ASCT was guided by life-threatening autoinflammatory symptoms that were refractory to multiple therapies. Three patients are in durable complete remission 32, 38, and 37 months after ASCT. Two others are in complete remission response after 3 and 5 months. One unfortunately died post-ASCT. This report suggests that ASCT could be a curative option in patients with VEXAS syndrome and severe manifestations. Considering the complications and side effects of the procedure as well as the existence of other potential treatment, clinical trials are needed to define the subgroup of patients who will benefit from this strategy and its place in the therapeutic arsenal against VEXAS syndrome.

hematology
Azacitidine for patients with Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry

Thibault Comont,Mael Heiblig,Etienne Rivière,Louis Terriou,Julien Rossignol,Didier Bouscary,Virginie Rieu,Guillaume Le Guenno,Alexis Mathian,Achille Aouba,Julien Vinit,Jeremie Dion,Olivier Kosmider,Benjamin Terrier,Sophie Georgin‐Lavialle,Pierre Fenaux,Arsène Mekinian,Groupe Francophone des Myélodysplasies and MedecineINterne the French VEXAS study group,

DOI: https://doi.org/10.1111/bjh.17893

2021-10-14

British Journal of Haematology

Abstract:Azacitidine can be effective in myelodysplastic syndromes (MDS) associated with inflammatory/autoimmune diseases. Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) is a new monogenic autoinflammatory syndrome caused by somatic ubiquitin-like modifier-activating enzyme 1 (UBA1) mutation, often associated with MDS, whose treatment is difficult and not yet codified. Based on a French nationwide registry of 116 patients with VEXAS, we report the efficacy and safety of azacitidine treatment in 11 patients with VEXAS with MDS. Clinical response of VEXAS to azacitidine was achieved in five patients (46%), during 6, 8+, 12, 21, 27+ months respectively, suggesting that azacitidine can be effective in selected patients with VEXAS and associated MDS.

hematology
Case report: VEXAS syndrome with excellent response to treatment with azacitidine

Tzvika Porges,Elli Rosenberg,Ofir Wolach,Iftach Sagy,Yehonatan Sherf,Itai Levi

DOI: https://doi.org/10.1007/s00277-024-06072-5

2024-11-22

Annals of Hematology

Abstract:Vacuoles, E1 enzyme, X-linked, auto inflammatory, somatic (VEXAS) syndrome is an inflammatory disorder caused by somatic UBA1 variants and is characterized by late-onset systemic autoimmune inflammation and blood abnormalities. Glucocorticoids ameliorate symptoms effectively. However, other treatment options have limited efficacy and a transient effect. Herein, we describe a case of a 69-year-old male patient with VEXAS syndrome with skin, lung and hematologic involvement. He was treated with glucocorticoids and after the failure with anti IL-1 he began treatment with azacitidine with excellent hematological and clinical response. Azacitidine may be a suitable option for treating VEXAS syndrome, especially due to the relationship between inflammatory symptoms and response to azacitidine.

hematology
Role of allogeneic hematopoietic cell transplantation in VEXAS syndrome

Dias, Ajoy L.

DOI: https://doi.org/10.1007/s00277-024-05942-2

2024-08-23

Annals of Hematology

Abstract:VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a newly diagnosed syndrome comprising severe systemic inflammatory and hematological manifestations including myelodysplastic syndrome and plasma cell dyscrasia. Since its discovery four years ago, several groups have identified pleomorphic clinical phenotypes, but few effective medical therapies exist which include Janus Kinase (JAK) inhibitors, interleukin inhibitors (IL-1 and IL-6), and hypomethylating agents. Prospective trials are lacking at this time and most patients remain corticosteroid dependent. VEXAS has a high morbidity from frequent life threatening inflammatory symptoms and risk of progression to hematological malignancies and has an overall survival of 50% at 10 years. Allogeneic stem cell transplant (allo-HCT) is a curative option for this disease caused by somatic mutations in the UBA1 gene. Here we outline the role of allo-HCT in treating patients with VEXAS syndrome, highlighting the outcomes from several single-institution studies and case reports. Prospective trials will be required to precisely define the role of allo-HCT in the management of VEXAS syndrome.

hematology
VEXAS syndrome: complete molecular remission after hypomethylating therapy

Sockel, Katja

DOI: https://doi.org/10.1007/s00277-023-05611-w

2024-01-13

Annals of Hematology

Abstract:The VEXAS syndrome, a genetically defined autoimmune disease, associated with various hematological neoplasms has been attracting growing attention since its initial description in 2020. While various therapeutic strategies have been explored in case studies, the optimal treatment strategy is still under investigation and allogeneic cell transplantation is considered the only curative treatment. Here, we describe 2 patients who achieved complete molecular remission of the underlying UBA1 mutant clone outside the context of allogeneic HCT. Both patients received treatment with the hypomethylating agent azacitidine, and deep molecular remission triggered treatment de-escalation and even cessation with sustained molecular remission in one of them. Prospective studies are necessary to clarify which VEXAS patients will benefit most from hypomethylating therapy and to understand the variability in the response to different treatment strategies.

hematology
A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm

Peng Li,Shobi Venkatachalam,Daniela Ospina Cordona,Lorena Wilson,Tibor Kovacsovics,Karen A. Moser,Rodney R. Miles,David B. Beck,Tracy George,Srinivas K. Tantravahi

DOI: https://doi.org/10.1182/bloodadvances.2021005243

IF: 7.642

2022-01-13

Blood Advances

Abstract:Abstract VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is caused by somatic mutations in UBA1 and is identified by a genotype-driven method. This condition affects unrelated men with adultonset inflammatory syndromes in association with hematologic manifestations of peripheral cytopenia and bone marrow myeloid dysplasia. Although bone marrow vacuolization restricted to myeloid and erythroid precursors has been identified in patients with VEXAS, the detailed clinical and histopathological features of peripheral blood and bone marrows remain unclear. The current case report describes the characteristic hematologic findings in patients with VEXAS, including macrocytic anemia, thrombocytopenia, marked hypercellular bone marrow with granulocytic hyperplasia, megaloblastic changes in erythroid precursors, and the absence of hematogones in addition to prominent vacuoles in myeloid and erythroid precursor cells. Characterizing the clinical and hematologic features helps to raise awareness and improve diagnosis of this novel, rare, but potentially underrecognized disease. Prompt diagnosis expands the general knowledgeable and understanding of this disease, and optimal management may prevent patients from developing complications related to this refractory inflammatory syndrome and improve the overall clinical outcome.

hematology
Case report of a patient with VEXAS syndrome

Ioannis Tsourveloudis,Eleni C. Georgiadi,Georgios Vatalis,Paraskevi Kotsi

DOI: https://doi.org/10.1097/md.0000000000036738

IF: 1.6

2024-01-10

Medicine

Abstract:Hematological malignancies have always been a challenge for scientists because of the constant need to clarify these entities. Through better understanding of the clinical aspects as well as of the molecular pathways implicated in the pathogenesis of these diseases, we can tailor targeted therapies to achieve at least prolonged progression-free survival if not remission. [ 1 , 2 ]

medicine, general & internal
Case report: VEXAS syndrome: an atypical indolent presentation as sacroiliitis with molecular response to azacitidine

Roberto Pereira da Costa,Guilherme Sapinho,Matilde Bandeira,Joana Infante,Tiago Marques,Carla Mimoso Santos,João Forjaz de Lacerda,João Eurico Fonseca,José Carlos Romeu

DOI: https://doi.org/10.3389/fimmu.2024.1403808

IF: 7.3

2024-05-23

Frontiers in Immunology

Abstract:VEXAS syndrome is a recently described autoinflammatory syndrome caused by the somatic acquisition of UBA1 mutations in myeloid precursors and is frequently associated with hematologic malignancies, chiefly myelodysplastic syndromes. Disease presentation can mimic several rheumatologic disorders, delaying the diagnosis. We describe a case of atypical presentation resembling late-onset axial spondylarthritis, later progressing to a systemic inflammatory syndrome with chondritis, cutaneous vasculitis, and transfusion-dependent anemia, requiring high doses of steroids. Ruxolitinib was used as the first steroid-sparing strategy without response. However, azacitidine showed activity in controlling both inflammation and the mutant clone. This case raises the question of whether azacitidine's anti-inflammatory effects are dependent on or independent of clonal control. We discuss the potential relevance of molecular remission in VEXAS syndrome and highlight the importance of a multidisciplinary team for the care of such complex patients.

immunology
Successful treatment with fludarabine and cyclophosphamide in a VEXAS syndrome patient with associated myelodysplastic syndrome: a case report and systematic review

Polina Bellman,Jesus D. Gonzalez-Lugo,Moazzam Shahzad,Muhammad Kashif Amin,Muhammad Fareed Khalid,Nahid Suleman,Nausheen Ahmed,Anurag K. Singh,Abdulraheem Yacoub,Da Zhang,Joseph P. McGuirk,Muhammad Umair Mushtaq

DOI: https://doi.org/10.3389/fonc.2024.1383730

IF: 4.7

2024-04-11

Frontiers in Oncology

Abstract:Vacuoles, E1 syndrome, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a chronic inflammatory disorder that affects various organ systems. It is associated with hematologic malignancies and is generally refractory to therapies. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be considered for selected patients. We report a case wherein systemic and hematological manifestations completely resolved in a patient with VEXAS and associated myelodysplastic syndrome (MDS), following the administration of fludarabine and cyclophosphamide as part of the preparation for allo-HSCT. We conducted a systematic literature review and included 86 patients with VEXAS syndrome and associated MDS. Most cases presented with musculoskeletal involvement (71%) and anemia (72%) with lower-risk MDS. Most patients responded to corticosteroids (CS) but had a recurrence of symptoms with CS taper and were refractory to other immunosuppressive agents. Hypomethylating agents and Janus kinase inhibitors achieved a complete response in some cases. Further research is needed to develop more effective treatment strategies.

oncology
Allogenic haematopoietic stem cell transplantation in VEXAS: A review of 33 patients

Syed B. Ali,Carmelo Gurnari

DOI: https://doi.org/10.1007/s10067-024-07160-7

2024-10-19

Clinical Rheumatology

Abstract:Vacuolation, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a multisystem disease due to a genetic mutation in the ubiquitin-activating enzyme ( UBA1 ). Allogeneic haematopoietic stem cell transplantation (allo-HSCT) offers both therapeutic and cure but also carries significant risks. A review of VEXAS and HSCT cases was undertaken. Thirty-three patients were identified; majority males ( n = 32, 97.0%), median time from symptoms to HSCT: 3 years (IQR 2.0–4.8) and median age of 59 years (IQR 52.5–65.5). UBA1 mutation Met41Thr was most common (11/32, 34.4%). The median variant allele frequency was 56.5% (IQR 43.0–73.5) with no correlation with increasing age. Prior to HSCT, 4.5 (IQR 2.8–6) treatments were trialled. Peripheral blood HSCT (30/31, 96.8%) and HLA-matched, unrelated donor (18/32, 56.3%) were most common. Conditioning regimens varied, with reduced intensity treatment with fludarabine as a co-agent most frequently administered (12/31, 38.7%). Both acute and/or chronic GVHD (18/32, 56.3%) and infections were common (12/32, 37.5%). Overall, 27 individuals (81.8%) were alive, and those undergoing HSCT prospectively had median follow up of 9 months (IQR 3.8–14.4). Of the six deceased, infection was implicated in four. In 11 cases with post-HSCT molecular data, a complete eradication of UBA1 mutation was reported. In summary, while consensus treatment strategy regarding VEXAS is lacking, this review highlights HSCT may remain not only a therapeutic option but also enable cure. However, considerations regarding comorbidities, concurrent haematological disorders as well as overall risks of GVHD and infections need to be made.

rheumatology
Case report: diagnosis of VEXAS syndrome in a patient with therapy-resistant large vessel vasculitis

M. Boret,T. Malfait,M. BoretT. MalfaitDepartment of Nephrology,AZ Delta,Roeselare,Belgium

DOI: https://doi.org/10.1080/17843286.2024.2312627

2024-02-06

Acta Clinica Belgica

Abstract:VEXAS (Vacuoles, E1 enzyme, X-linked, Auto-Inflammatory, Somatic) syndrome is a recently identified multisystemic auto-inflammatory condition caused by somatic mutations in the UBA1 gene. This syndrome presents diagnostic challenges due to its rare nature and varied clinical manifestations. We report the clinical course of a 76-year-old man with therapy-resistant large vessel vasculitis and myelodysplastic syndrome (MDS), eventually confirmed as VEXAS syndrome. The patient responded well to corticosteroid therapy. However, over two years, he faced multiple hospital admissions due to inflammatory flare-ups during corticosteroid tapering. Several immunosuppressive therapies were attempted without success. Further research is essential to understand this complex syndrome's pathophysiology, genetics, clinical course, and treatment options, ultimately benefiting both patients and healthcare providers.

medicine, general & internal
VEXAS anemia is a mosaic erythroblastopenia

Francois Rodrigues,Giulia Hardouin,Sara El Hoss,Aya Ghoul,Emilie-Fleur Gautier,Michael Dussiot,Sandy Peltier,Pascal Amireault,Vanessa Soldan,Annarita Miccio,Mounia Debili,Vincent Jachiet,Thiago Trovati,Julien Rossignol,Eric Allemand,Arsene Mekinian,Sophie Georgin-Lavialle,Mohammad Salma,Eric Soler,Pierre-Emmanuel Gleizes,Marie-Francoise O'Donohue,Olivier Kosmider,Manuel Rodriguez,Olivier Hermine

DOI: https://doi.org/10.1101/2024.12.02.623560

2024-12-04

Abstract:VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a recently discovered autoinflammatory disorder linked to somatic mutations in the UBA1 gene, resulting in a profound cytoplasm-restricted defect in ubiquitylation. The disease is characterized by a macrocytic anemia that remains poorly understood. To investigate the erythroid lineage in VEXAS, we conducted a comprehensive study combining in vivo assessments of patients' mature red cells and marrow erythroblasts, alongside in vitro base-editing models of erythropoiesis. Here we show that mature red cells do not exhibit ubiquitylation defects, and patient-derived bone marrow erythroblasts lack UBA1 mutations beyond the basophilic stage of erythroid differentiation. In vitro knock-in of UBA1 variants in CD34+ primary cells resulted in high mortality during early erythroid differentiation, but not during monocytic differentiation. Edited erythroid precursors displayed TP53 overexpression linked to defective ubiquitylation and anomalies in ribosome biogenesis, reminiscent of Diamond-Blackfan anemia. We propose that VEXAS-associated anemia should be considered as a mosaic erythroblastopenia, where the severity of anemia is influenced by the quality and quantity of the UBA1-WT compartment. These insights may aid clinicians in tailoring treatment strategies.

Cell Biology
15-Days Duration of Venetoclax Combined with Azacitidine in the Treatment of Relapsed/Refractory High-Risk Myelodysplastic Syndromes: A Retrospective Single-Center Study

Chen Mei,Li Ye,Yanling Ren,Xinping Zhou,Liya Ma,Gaixiang Xu,Weilai Xu,Chenxi Lu,Haiyang Yang,Yingwan Luo,Lingxu Jiang,Wei Lang,HongHu Zhu,Jie Jin,Hongyan Tong

DOI: https://doi.org/10.1182/blood-2022-168938

IF: 4.85

2023-01-01

Hematological Oncology

Abstract:The treatment of patients with refractory and/or relapsed (R/R) high-risk myelodysplastic syndrome (HR-MDS) remains a daunting clinical challenge. Venetoclax is a selective BCL-2 inhibitor, which combined with hypomethylating agents (HMAs), increased responses and prolonged survival in unfit and previously untreated acute myeloid leukemia. We performed a retrospective study of patients with R/R HR-MDS receiving combination azacytidine (AZA) plus 15-days duration of venetoclax (VEN-15d) in order to determine their efficacy and toxicity in this context. We showed that the overall response rate was 57.2% (20/35) and the median over survival was 14 months in R/R MDS. The most common treatment-emergent adverse events were peripheral blood cytopenias and infectious complications. Our retrospective study showed that the real-world experience of treating R/R MDS with AZA plus VEN-15d highlights an encouraging response rate with myelosuppression being the major toxicity. Of note, VEN-15d with AZA may salvage patients failing to respond optimally to HMAs and reduce the disease-burden for subsequent allogeneic stem cell transplantation in our analysis. These data of combination AZA plus VEN-15d in R/R MDS warrant further prospective evaluation in clinical trials.
Comprehensive morphologic characterization of bone marrow biopsy findings in a large cohort of patients with VEXAS syndrome: A single-institution longitudinal study of 111 bone marrow samples from 52 patients

Horatiu Olteanu,Mrinal Patnaik,Matthew J Koster,Jennifer L Herrick,Dong Chen,Rong He,David Viswanatha,Kenneth J Warrington,Ronald S Go,Abhishek A Mangaonkar,Taxiarchis Kourelis,Alexander Hines,Sarah E Gibson,Jess F Peterson,Kaaren K Reichard

DOI: https://doi.org/10.1093/ajcp/aqad186

2024-02-27

American Journal of Clinical Pathology

Abstract:Abstract Objectives VEXAS syndrome is an adult-onset autoinflammatory disease caused by a somatic pathogenic mutation in the UBA1 (ubiquitin-like modifier activating enzyme 1) gene. Patients present with rheumatologic manifestations and cytopenias and may have an increased predisposition to myelodysplastic syndrome (MDS) and plasma cell neoplasms. Prior studies have reported on the peripheral blood and bone marrow findings in patients with VEXAS syndrome. Due to the protean clinical presentation and lack of specificity of morphologic features (eg, vacuoles in early erythroid and granulocytic precursors), an optimal screening methodology to identify these patients in a timely fashion is desirable. Methods To further evaluate and describe the salient diagnostic morphologic features in VEXAS syndrome, we carried out a comprehensive study of the largest single-institution cohort to date. Diagnostic and follow-up bone marrow biopsy specimens from 52 male patients with molecularly identified VEXAS syndrome underwent central review. Results Cytopenias were common in all cases, primarily macrocytic anemia, monocytopenia, and thrombocytopenia. Bone marrow aspirate and biopsy were often hypercellular, with an increased myeloid/erythroid ratio, granulocytic hyperplasia with left shift, erythroid left shift, and megakaryocyte hyperplasia, which exhibited a range of striking morphologic findings. Distinctly vacuolated myeloid and erythroid precursors were seen in more than 95% of cases. Conclusions Our data reveal potential novel diagnostic features, such as a high incidence of monocytopenia and distinct patterns of atypical megakaryopoiesis, that appear different from dysmegakaryopoiesis typically associated with MDS. In our experience, those findings are suggestive of VEXAS, in the appropriate clinical context.

pathology
VEXAS Syndrome: an update

Mohamed-Yacine Khitri,Jérôme Hadjadj,Arsène Mekinian,Vincent Jachiet

DOI: https://doi.org/10.1016/j.jbspin.2024.105700

IF: 5.263

2024-02-03

Joint Bone Spine

Abstract:VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a recently described autoinflammatory syndrome, mostly affecting men older than 50 years, caused by somatic mutation in the UBA1 gene, a X-linked gene involved in the activation of ubiquitin system. Patients present a broad spectrum of inflammatory manifestations (fever, neutrophilic dermatosis, chondritis, pulmonary infiltrates, ocular inflammation, venous thrombosis) and hematological involvement (macrocytic anemia, thrombocytopenia, vacuoles in myeloid and erythroid precursor cells, dysplastic bone marrow) that are responsible for a significant morbidity and mortality. The therapeutic management is currently poorly codified but is based on two main approaches: controlling inflammatory symptoms (by using corticosteroids, JAK inhibitor or tocilizumab) or targeting the UBA1 -mutated hematopoietic population (by using azacitidine or allogeneic hematopoietic stem cell transplantation). Supportive care is also important and includes red blood cell or platelet transfusions, erythropoiesis stimulating agents, thromboprophylaxis and anti-infectious prophylaxis. The aim of this review is to provide a current overview of the VEXAS syndrome, particularly focusing on its pathophysiological, diagnostic and therapeutic aspects.

rheumatology
An Interdisciplinary Challenge

Virginie Kreutzinger,Anne Pankow,Zhivana Boyadzhieva,Udo Schneider,Katharina Ziegeler,Lars Uwe Stephan,Jan Carl Kübke,Sebastian Schröder,Christian Oberender,Philipp le Coutre,Sebastian Stintzing,Ivan Jelas

DOI: https://doi.org/10.3390/jcm13041049

IF: 3.9

2024-02-13

Journal of Clinical Medicine

Abstract:VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently recognized systemic autoinflammatory disease caused by somatic mutations in hematopoietic progenitor cells. This case series of four patients with VEXAS syndrome and comorbid myelodysplastic syndrome (MDS) aims to describe clinical, imaging, and hematologic disease presentations as well as response to therapy. Four patients with VEXAS syndrome and MDS are described. A detailed analysis of imaging features, hemato-oncological presentation including bone marrow microscopy and clinical–rheumatological disease features and treatment outcomes is given. All patients were male; ages ranged between 64 and 81 years; all were diagnosed with MDS. CT imaging was available for three patients, all of whom exhibited pulmonary infiltrates of varying severity, resembling COVID-19 or hypersensitivity pneumonitis without traces of scarring. Bone marrow microscopy showed maturation-disordered erythropoiesis and pathognomonic vacuolation. Somatic mutation in the UBA1 codon 41 were found in all patients by next-generation sequencing. Therapy regimes included glucocorticoids, JAK1/2-inhibitors, nucleoside analogues, as well as IL-1 and IL-6 receptor antagonists. No fatalities occurred (observation period from symptom onset: 18–68 months). Given the potential underreporting of VEXAS syndrome, we highly recommend contemporary screening for UBA1 mutations in patients presenting with ambiguous signs of systemic autoinflammatory symptoms which persist over 18 months despite treatment. The emergence of cytopenia, especially macrocytic hyperchromic anemia, should prompt early testing for UBA1 mutations. Notably conspicuous, pulmonary alterations in CT imaging of patients with therapy-resistant systemic autoinflammatory symptoms should be discussed in interdisciplinary medical teams (Rheumatology, Hematology, Radiology and further specialist departments) to facilitate timely diagnosis during the clinical course of the disease.

medicine, general & internal
Bone marrow reinvestigation leading to the diagnosis of VEXAS syndrome

Bernhard Strasser,Wolfgang Kranewitter,Harald Hofer,Alexander Haushofer

DOI: https://doi.org/10.1093/labmed/lmae020

IF: 1.865

2024-03-26

Laboratory Medicine

Abstract:Abstract A 46-year-old male patient presented with inflammatory diseases over more than 3 years. The patient suffered from recurrent pleuritis, polychondritis, orbital phlegmon, fever, and skin lesions. A bone marrow puncture added myelodysplastic syndrome to the patient’s history. A focused cytomorphological reinvestigation of the archived bone marrow aspirate smears detected significant vacuolization of erythroid and myeloid precursor cells. Target sequencing revealed the UBA1 (p.Met41Thr) hotspot mutation that established the diagnosis of VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome.

medical laboratory technology
VEXAS Syndrome: Clinical Case Series From a Canadian Cohort

Stephen Williams,Mohan Stewart,Aurore Fifi-Mah,Natasha Dehghan

DOI: https://doi.org/10.3899/jrheum.2022-0226

2024-03-15

The Journal of Rheumatology

Abstract:VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic; OMIM #301054) syndrome is an autoinflammatory condition first described in November 2020. 1 It is characterized by vacuoles in myeloid and erythroid precursor cells on bone marrow biopsy and caused by a monogenic somatic mutation in the ubiquitin-like modifier activating enzyme 1 ( UBA1 ) gene. 1,2

rheumatology
VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder

Huijun Huang,Wenjun Zhang,Wenyu Cai,Jinqin Liu,Huijun Wang,Tiejun Qin,Zefeng Xu,Bing Li,Shiqiang Qu,Lijuan Pan,Gang Huang,Robert Peter Gale,Zhijian Xiao

DOI: https://doi.org/10.1186/s40164-021-00217-2

2021-03-19

Experimental Hematology and Oncology

Abstract:Abstract VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a newly-described adult-onset inflammatory syndrome characterized by vacuoles in myeloid and erythroid precursor cells and somatic mutations affecting methionine-41 (p.Met41) in UBA1 . The VEXAS syndrome often overlaps with myelodysplastic syndromes (MDS) with autoimmune disorders (AD). By screening the UBA1 gene sequences derived from MDS patients with AD from our center, we identified one patient with a p.Met41Leu missense mutation in UBA1 , who should have been diagnosed as MDS comorbid with VEXAS syndrome. This patient respond poorly to immune suppressive drugs. Patients with MDS and AD who have characteristic vacuoles in myeloid and erythroid precursor cells should be screened for UBA1 mutation, these patients are likely to have VEXAS syndrome and unlikely to improve with immunosuppressive drugs and should be considered for other alternative therapies.

oncology,hematology

Could it be VEXAS?

Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report

Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience

Azacitidine for patients with Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry

Case report: VEXAS syndrome with excellent response to treatment with azacitidine

Role of allogeneic hematopoietic cell transplantation in VEXAS syndrome

VEXAS syndrome: complete molecular remission after hypomethylating therapy

A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm

Case report of a patient with VEXAS syndrome

Case report: VEXAS syndrome: an atypical indolent presentation as sacroiliitis with molecular response to azacitidine

Successful treatment with fludarabine and cyclophosphamide in a VEXAS syndrome patient with associated myelodysplastic syndrome: a case report and systematic review

Allogenic haematopoietic stem cell transplantation in VEXAS: A review of 33 patients

Case report: diagnosis of VEXAS syndrome in a patient with therapy-resistant large vessel vasculitis

VEXAS anemia is a mosaic erythroblastopenia

15-Days Duration of Venetoclax Combined with Azacitidine in the Treatment of Relapsed/Refractory High-Risk Myelodysplastic Syndromes: A Retrospective Single-Center Study

Comprehensive morphologic characterization of bone marrow biopsy findings in a large cohort of patients with VEXAS syndrome: A single-institution longitudinal study of 111 bone marrow samples from 52 patients

VEXAS Syndrome: an update

An Interdisciplinary Challenge

Bone marrow reinvestigation leading to the diagnosis of VEXAS syndrome

VEXAS Syndrome: Clinical Case Series From a Canadian Cohort

VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder